One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback